Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

327.36 +12.96 (+4.12%)
Streaming Delayed Price Updated: 9:47 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
The 3 Best Gene Editing Stocks to Buy in August 2024 ↗
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. 
Via InvestorPlace
News headline image
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
News headline image
How Is The Market Feeling About Alnylam Pharmaceuticals? ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today ↗
 
Via Benzinga
News headline image
Peering Into Alnylam Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Peering Into Alnylam Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio? ↗
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
News headline image
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
News headline image
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Stock Is a Blockbuster Biopharma In the Making ↗
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market. 
Via InvestorPlace
News headline image
35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success. ↗
Alnylam Pharmaceuticals stock recently popped and could continue to move higher on Alnylam Pharmaceuticals' cardiovascular drug announcement. 
Via InvestorPlace
News headline image
7 Cheap Biotech Stocks With Major Upside Potential ↗
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
News headline image
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip? ↗
Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices. 
Via The Motley Fool
News headline image
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO ↗
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
News headline image
$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows ↗
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged. 
Via Benzinga
Topics ETFs
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio? ↗
The top 10 large-cap stocks in the last week were RIVN, CUK, FDX, IOT, SUZ, CVNA, FTAI, RDDT, MDB, and ALNY. Many analysts have raised their price forecasts for these stocks. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21, 
Via Benzinga
Topics Stocks
News headline image
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday? ↗
Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains... 
Via Benzinga
Topics Stocks
News headline image
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears ↗
A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees. 
Via InvestorPlace
News headline image
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success ↗
The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare. 
Via InvestorPlace
News headline image
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge ↗
Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and... 
Via Benzinga
News headline image
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug ↗
The companies are working on treatments for ATTR amyloidosis with cardiomyopathy. 
Via Investor's Business Daily
News headline image
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.